Alzamend Neuro IncNASDAQ:ALZN
- LAST PRICE1.3100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.3100/ 4
- Ask / Lots1.3600/ 13
- Open / Previous Close1.3000 / 1.3100
- Day Range
- 52 Week Range
- Volume181,307
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALZN |
|---|---|---|
| 09:32 ET | 2944 | 1.3202 |
| 09:42 ET | 384 | 1.31 |
| 09:44 ET | 1200 | 1.31 |
| 09:46 ET | 500 | 1.315 |
| 09:55 ET | 1982 | 1.31 |
| 09:57 ET | 1400 | 1.31 |
| 10:00 ET | 1245 | 1.31 |
| 10:02 ET | 500 | 1.31 |
| 10:09 ET | 600 | 1.32 |
| 10:15 ET | 1545 | 1.31 |
| 10:22 ET | 891 | 1.32 |
| 10:24 ET | 1798 | 1.31 |
| 10:26 ET | 3557 | 1.31 |
| 10:27 ET | 300 | 1.325 |
| 10:29 ET | 2652 | 1.3294 |
| 10:31 ET | 2300 | 1.32 |
| 10:36 ET | 17530 | 1.32 |
| 10:38 ET | 5303 | 1.33 |
| 10:40 ET | 1268 | 1.3399 |
| 10:42 ET | 3451 | 1.3368 |
| 10:45 ET | 15695 | 1.33 |
| 10:49 ET | 100 | 1.34 |
| 10:56 ET | 3684 | 1.34 |
| 10:58 ET | 200 | 1.34 |
| 11:00 ET | 3000 | 1.3302 |
| 11:02 ET | 200 | 1.3399 |
| 11:03 ET | 3122 | 1.33 |
| 11:09 ET | 1000 | 1.3299 |
| 11:14 ET | 300 | 1.32 |
| 11:20 ET | 1039 | 1.3499 |
| 11:25 ET | 238 | 1.3414 |
| 11:27 ET | 111 | 1.3499 |
| 11:30 ET | 381 | 1.3485 |
| 11:34 ET | 7603 | 1.34 |
| 11:36 ET | 200 | 1.3482 |
| 11:38 ET | 300 | 1.35 |
| 11:39 ET | 200 | 1.3407 |
| 11:41 ET | 312 | 1.34 |
| 11:45 ET | 1415 | 1.34 |
| 11:54 ET | 300 | 1.34 |
| 11:56 ET | 112 | 1.34 |
| 12:06 ET | 800 | 1.35 |
| 12:15 ET | 100 | 1.35 |
| 12:19 ET | 400 | 1.3421 |
| 12:21 ET | 122 | 1.3489 |
| 12:28 ET | 100 | 1.35 |
| 12:39 ET | 200 | 1.34 |
| 12:50 ET | 3700 | 1.33 |
| 01:06 ET | 1600 | 1.33 |
| 01:11 ET | 120 | 1.3309 |
| 01:20 ET | 453 | 1.3301 |
| 01:24 ET | 1500 | 1.3399 |
| 01:27 ET | 200 | 1.33 |
| 01:29 ET | 186 | 1.3393 |
| 01:33 ET | 200 | 1.335 |
| 01:36 ET | 1000 | 1.34 |
| 01:42 ET | 3851 | 1.33 |
| 01:51 ET | 401 | 1.345 |
| 02:03 ET | 335 | 1.3405 |
| 02:12 ET | 100 | 1.36 |
| 02:14 ET | 2829 | 1.36 |
| 02:16 ET | 2100 | 1.36 |
| 02:30 ET | 900 | 1.36 |
| 02:36 ET | 200 | 1.35 |
| 02:39 ET | 100 | 1.35 |
| 02:48 ET | 1476 | 1.335 |
| 02:54 ET | 2700 | 1.34 |
| 03:12 ET | 598 | 1.33 |
| 03:17 ET | 100 | 1.34 |
| 03:24 ET | 402 | 1.33 |
| 03:26 ET | 5015 | 1.345 |
| 03:28 ET | 800 | 1.345 |
| 03:30 ET | 900 | 1.34 |
| 03:32 ET | 10200 | 1.335 |
| 03:33 ET | 12577 | 1.31 |
| 03:37 ET | 11785 | 1.31 |
| 03:42 ET | 4534 | 1.3 |
| 03:50 ET | 468 | 1.3 |
| 03:55 ET | 1550 | 1.3 |
| 03:57 ET | 100 | 1.3 |
| 04:00 ET | 3654 | 1.31 |
Nov 19, 2024
Nov 11, 2024
DJ Alzamend Neuro Is Maintained at Buy by Ascendiant Capital, from 4:45AM ET on Monday Nov 11, 2024 by Dow Jones
4:45AM ET on Monday Nov 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alzamend Neuro Inc | 5.9M | -0.1x | --- |
Alterola Biotech Inc | 5.8M | -2.4x | --- |
Bionomics Ltd | 5.8M | 0.0x | --- |
Aptevo Therapeutics Inc | 5.7M | 0.0x | --- |
Agentix Corp | 6.0M | -20.3x | --- |
Enzon Pharmaceuticals Inc | 5.6M | 21.4x | -60.21% |
Company Information
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
Contact Information
- Headquarters
- 3480 Peachtree Road NE , Second Floor, Suite 103ATLANTA, GA, United States 30326
- Phone
- 302-636-5400
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- William Horne
- Chief Executive Officer, Director
- Stephan Jackman
- Vice Chairman of the Board
- Milton Ault
- Chief Financial Officer
- David Katzoff
- Executive Vice President, General Counsel, Director
- Henry Nisser
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 4.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.05 |
EPS | $-10.69 |
Book Value | $-3.77 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
